|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
21,170,000 |
Market
Cap: |
8.16(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2102 - $1.4 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile InVivo Therapeutics Holdings is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. Co.'s Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The Neuro-Spinal Scaffold implant is intended to provide support to the surrounding tissue after injury, minimize expansion of areas of necrosis, and provide a biomaterial substrate for the body's own healing/repair processes following injury. The Neuro-Spinal Scaffold is composed of poly lactic-co-glycolic acid and Poly-L-Lysine biocompatible and bioresorbable polymers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
330,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$123,030 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Roberts Richard John |
Director |
|
2016-08-19 |
4 |
OE |
$0.29 |
$20,328 |
D/D |
70,000 |
127,500 |
|
- |
|
Roberts Richard John |
Director |
|
2016-02-10 |
4 |
OE |
$0.29 |
$10,164 |
D/D |
35,000 |
65,000 |
|
- |
|
Ulich Thomas R |
Chief Scientific Officer |
|
2015-12-31 |
5 |
A |
$6.12 |
$1,622 |
D/D |
265 |
21,693 |
|
- |
|
Perrin Mark D |
CHIEF EXECUTIVE OFFICER |
|
2015-12-31 |
5 |
A |
$6.12 |
$6,444 |
D/D |
1,053 |
58,195 |
|
- |
|
Joseph Tamara L |
SVP, General Counsel |
|
2015-12-31 |
5 |
A |
$6.12 |
$9,786 |
D/D |
1,599 |
17,027 |
|
- |
|
Mcallister Steven F |
Chief Financial Officer |
|
2015-12-31 |
5 |
A |
$6.12 |
$1,420 |
D/D |
232 |
19,160 |
|
- |
|
Lorianne Masuoka K. |
Chief Medical Officer |
|
2015-12-31 |
5 |
A |
$6.12 |
$1,622 |
D/D |
265 |
265 |
|
- |
|
Roberts Richard John |
Director |
|
2015-12-29 |
4 |
OE |
$0.29 |
$5,808 |
D/D |
20,000 |
30,000 |
|
- |
|
Merrifield C Ann |
Director |
|
2015-08-12 |
4 |
B |
$12.36 |
$24,718 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
Perrin Mark D |
CHIEF EXECUTIVE OFFICER |
|
2014-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
57,142 |
57,142 |
|
- |
|
Ulich Thomas R |
Chief Scientific Officer |
|
2014-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
21,428 |
21,428 |
|
- |
|
Joseph Tamara L |
SVP, General Counsel |
|
2014-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,428 |
15,428 |
|
- |
|
Mcallister Steven F |
Chief Financial Officer |
|
2014-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,928 |
18,928 |
|
- |
|
Roberts Richard John |
Director |
|
2014-08-08 |
4 |
OE |
$0.07 |
$726 |
D/D |
10,000 |
10,000 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-05-09 |
4 |
S |
$1.20 |
$15,000 |
D/D |
(12,500) |
9,045,920 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-05-08 |
4 |
S |
$1.19 |
$14,875 |
D/D |
(12,500) |
9,058,420 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-05-07 |
4 |
S |
$1.20 |
$30,000 |
D/D |
(25,000) |
9,070,920 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-05-05 |
4 |
S |
$1.79 |
$37,948 |
D/D |
(21,200) |
9,083,420 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-05-02 |
4 |
S |
$2.05 |
$7,790 |
D/D |
(3,800) |
9,095,920 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-05-01 |
4 |
S |
$1.95 |
$24,375 |
D/D |
(12,500) |
9,108,420 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-04-30 |
4 |
S |
$1.89 |
$23,625 |
D/D |
(12,500) |
9,120,920 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-04-29 |
4 |
S |
$1.82 |
$22,750 |
D/D |
(12,500) |
9,133,420 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-04-28 |
4 |
S |
$1.76 |
$22,000 |
D/D |
(12,500) |
9,145,920 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-04-25 |
4 |
S |
$1.51 |
$18,875 |
D/D |
(12,500) |
9,158,420 |
|
- |
|
Reynolds Francis |
10% Owner |
|
2014-04-24 |
4 |
S |
$1.51 |
$18,875 |
D/D |
(12,500) |
9,170,920 |
|
- |
|
458 Records found
|
|
Page 2 of 19 |
|
|